Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Cost of Revenue (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Cost of Revenue for 6 consecutive years, with -$4.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 106.91% to -$4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $88.4 million, a 20.39% decrease, with the full-year FY2025 number at $88.4 million, down 20.39% from a year prior.
  • Cost of Revenue was -$4.2 million for Q4 2025 at GeneDx Holdings, down from $32.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $158.3 million in Q4 2022 to a low of -$4.2 million in Q4 2025.
  • A 5-year average of $43.9 million and a median of $33.3 million in 2022 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 416.02% in 2021, then tumbled 106.91% in 2025.
  • GeneDx Holdings' Cost of Revenue stood at $60.6 million in 2021, then surged by 161.24% to $158.3 million in 2022, then tumbled by 76.03% to $37.9 million in 2023, then surged by 61.7% to $61.4 million in 2024, then crashed by 106.91% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Cost of Revenue are -$4.2 million (Q4 2025), $32.2 million (Q3 2025), and $31.8 million (Q2 2025).